Long-term health consequences of polycystic ovary syndrome

Polycystic Ovary Syndrome, Second Edition

Volumn , Issue , 2007, Pages 81-101

  Kousta, Eleni ^a   Franks, Stephen ^b  

^a Institute of Reproductive and Developmental Biology Imperial College London Hammersmith Hospital ^*  (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649863323     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545191.007     Document Type: Chapter

References (115)

1. Abbott D. H., Dumesic D. A., and Franks S. (2002) Developmental origin of polycystic ovary syndrome: a hypothesis. J. Endocrinol. 174:1-5.
2. Andersen P., Seljeflot I., Abdelnoor M., et al. (1995) Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44:611-616.
3. Anttila L., Karjala K., Penttila R. A., Ruutiainen K., and Ekblad U. (1998) Polycystic ovaries in women with gestational diabetes. Obstet. Gynecol. 92:13-16.
4. Arslanian S. A., Lewy V.D., and Danadian K. (2001) Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease J. Clin. Endocrinol. Metab. 86:66-71.
5. Asunción M., Calvo R. M., San Millan J. L., et al. (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85:2434-2438.
6. Austin M. A., Breslow J. L., Hennekens C. H., et al. (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. J. Am. Med. Assoc. 260:1917-1921.
7. Balen A. (2001) Polycystic ovary syndrome and cancer. Hum. Reprod. Update 7:522-525.
8. Balen A. H., Conway G. S., Kaltsas G., et al. (1995) Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod. 10:2107-2111.
9. Bass K. M., NewschaVer C. J., Klag M. J., and Bush T. L. (1993) Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch. Intern. Med. 153:2209-2216.
10. Birdsall M. A., Farquhar C. M., and White H.D. (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann. Intern. Med. 126:32-35.
11. Blackburn R., Giral P., Bruckert E., et al. (2001) Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 21:1962-1968.
12. Burghen G. A., Givens J. R., and Kitabchi A. E. (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50:113-116.
13. Christian R. C., Dumesic D. A., Behrenbeck T., et al. (2003) Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88:2562-2568.
14. Colilla S., Cox N. J., and Ehrmann D. A. (2001) Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J. Clin. Endocrinol. Metab. 86:2027-2031.
15. Conway G. S., Jacobs H. S., Holly J. M., and Wass J. A. (1990) EVects of luteinizing hormone, insulin, insulin-like growth factor-1 and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 33:593-603.
16. Coulam C. B., Annegers J. F., and Kranz J. S. (1983) Chronic anovulation syndrome and associated neoplasia. Obstet. Gynecol. 61:403-407.
17. Dahlgren E., Friberg L. G., Johansson S., et al. (1991) Endometrial carcinoma: ovarian dysfunction-a risk factor in young women. Eur. J. Obstet. Gynecol. Reprod. Biol. 41:143-150.
18. Dahlgren E., Johansson S., Lindstedt G., et al. (1992a) Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil. Steril. 57:505-513.
19. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. (1992b) Polycystic ovary syndrome and risk for myocardial infarction, evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 71:599-604.
20. Diamanti-Kandarakis E., Kouli C. R., Bergiele A. T., et al. (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84:4006-4011.
21. Diamanti-Kandarakis E., Spina G., Kouli C., and Migdalis I. (2001) Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial eVect of metformin therapy. J. Clin. Endocrinol. Metab. 86:4666-4673.
22. Dunaif A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism of action and implications for pathogenesis. Endocr. Revi. 18:774-800.
23. Dunaif A. and Finegood D. T. (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:942-947.
24. Dunaif A., Graf M., Mandeli J., Laumas V., and Dobrjansky A. (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J. Clin. Endocrinol. Metab. 65:499-507.
25. Dunaif A., Segal K. R., Futterweit W., and Dobrjansky A. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174.
26. Ehrmann D. A., Sturis J., Byrne M. M., et al. (1995) Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 96:520-527.
27. Ehrmann D. A., Barnes R. B., Rosenfield R. L., Cavaghan M. K., and Imperial J. (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141-146.
28. Eisner J. R., Barnett M.A., Dumesic D.A., and Abbott D. H. (2002) Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil. Steril. 77:167-172.
29. Escobedo L. G., Lee N. C., Peterson H. B., and Wingo P. A. (1991) Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet. Gynecol. 77:124-128.
30. Fernandez-Castaner M., Biarnes J., Camps I., et al. (1996) Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus. Diabet. Med. 13:953-959.
31. Ferrannini E., Natali A., Bell P., et al. (1997) Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR). J. Clin. Invest. 100:1166-1173.
32. Ferri C., Pittoni V., Piccoli A., et al. (1995) Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J. Clin. Endocrinol. Metab. 80:829-835.
33. Festa A., D'Agostino Jr. R., Howard G., et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102:42-47.
34. Folsom A. R., Pankow J. S., Tracy R. P., et al. (2001) Investigators of the NHBLI Family Heart Study: association of C-reactive protein with markers of prevalent atherosclerotic disease. Am. J. Cardiol. 88:112-117.
35. Franks S. (1995) Polycystic ovary syndrome. N. Engl. J. Med. 333:853-861.
36. Franks S. (2001) Are women with polycystic ovary syndrome at increased risk of cardiovascular disease? Too early to be sure, but not too early to act! Am. J. Med. 111:665-666.
37. Freeman D. J., Norrie J., Caslake M. J., et al. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600.
38. Furberg A. S. and Thune I. (2003) Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int. J. Cancer. 104:669-676.
39. Gambineri A., Pelusi C., Manicardi E., et al. (2004) Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53:2353-2358.
40. Goldzieher J.W. and Green J. A. (1962) The polycystic ovary. I. Clinical and histologic features. J. Clin. Endocrinol. Metab. 22:325-338.
41. Guzick D. S., Talbott E.O., Sutton-Tyrrell K., et al. (1996) Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am. J. Obstet. Gynecol. 174:1224-1229; discussion 1229-1232.
42. Hamilton-Fairley D., Kiddy D., Watson H., Paterson C., and Franks S. (1992) Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br. J. Obstet. Gynaecol. 99:128-131.
43. Hardiman P., Pillay O. C., and Atiomo W. (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361:1810-1812.
44. Harris M. I., HaddenW. C., KnowlerW. C., and Bennett P. H. (1987) Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr. Diabetes 36:523-534.
45. Holte J., Bergh T., Berne C., Berglund L., and Lithell H. (1994) Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J. Clin. Endocrinol. Metab. 78:1052-1058.
46. Holte J., Bergh T., Berne C., Wide L., and Lithell H. (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80:2586-2593.
47. Holte J., Gennarelli G., Wide L., Lithell H., and Berne C. (1998) High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J. Clin. Endocrinol. Metab. 83:1143-1150.
48. Ibañez L., Dimartino-Nardi J., Potau N., and Saenger P. (2000) Premature adrenarche: normal variant or forerunner of adult disease? Endocr. Rev. 21:671-696.
49. Kahn S. E., Prigeon R. L., McCulloch D. K., et al. (1993) Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: Evidence for a hyperbolic function. Diabetes 42:1663-1672.
50. Kelly C. C. J., Lyall H., Petrie J. R., et al. (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 86:2453-2455.
51. Kelly C. J. G., Speirs A., Gould G.W., et al. (2002) Altered vascular function in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87:742-746.
52. Kiddy D. S., Sharp P. S., White D. M., Scanlon M. F., et al. (1990) DiVerences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin. Endocrinol. (Oxf.) 32:213-220.
53. Kiddy D. S., Hamilton-Fairley D., Bush A., et al. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 36:105-111.
54. King H., and Rewers M. (1993) Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 16:157-177.
55. Knochenhauer E. S., Key T. J., Kahsar-Miller M., et al. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 83:3078-3082.
56. Kousta E., White D. M., and Franks S. (1997) Modern use of clomiphene citrate in induction of ovulation. Hum. Reprod. Update. 3:359-365.
57. Kousta E., Cela E., Lawrence N. J., et al. (2000) The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin. Endocrinol. 53:501-507.
58. Kousta E., Lawrence N. J., Godsland I. F., et al. (2003) Insulin resistance and beta-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Clin. Endocrinol. 59:289-297.
59. Kuczmarski R. J., Flegal K. M., Campbell S. M., and Johnson C. L. (1994) Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. J. Am. Med. Assoc. 272:205-211.
60. Kuller L. H., Tracy R. P., Shaten J., and Meilahn E. N. (1996) Relation of C-reactive protein and coronary heart disease in the Multiple Risk Factor Intervention Trial nested case-control study. Am. J. Epidemiol. 144:537-547.
61. Laitinen J., Taponen S., Martikainen H., et al. (2003) Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int. J. Obes. Relat. Metab. Disord. 27:710-715.
62. Legro R. S., Kunselman A. R., DodsonW. C., and Dunaif A. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 aVected women. J. Clin. Endocrinol. Metab. 84:165-169.
63. Legro R. S., Kunselman A. R., and Dunaif A. (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111:607-613.
64. Legro R. S., Bentley-Lewis R., Driscoll D., Wang S. C., and Dunaif A. (2002) Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J. Clin. Endocrinol. Metab. 87:2128-2133.
65. Lerman A., Edwards B. S., Hallett J.W., et al. (1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325:997-1001.
66. Lewy V.D., Danadian K., Witchel S. F., and Arslanian S. (2001) Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J. Pediatr. 138:38-44.
67. Manson J. E., Colditz G. A., Stampfer M. J., et al. (1990) A prospective study of obesity and risk of coronary heart disease in women. N. Engl. J. Med. 322:882-889.
68. Mather K. J., Kwan F., and Corenblum B. (2000a) Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil. Steril. 73:150-156.
69. Mather K. J., Verma S., Corenblum B., and Anderson T. J. (2000b) Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85:1851-1856.
70. Mather K. J., Mirzamohammadi B., Lteif A., Steinberg H.O., and Baron A.D. (2002) Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51:3517-3523.
71. Norman R. J. and Clark A. M. (1998) Obesity and reproductive disorders: a review. Reprod. Fertil. Dev. 10:55-63.
72. Norman R. J., Masters S. C., Hague W., et al. (1995) Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil. Steril. 63:329-335.
73. Norman R. J., Masters S., and Hague W. (1996) Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil. Steril. 66:942-947.
74. Norman R. J., Davies M. J., Lord J., and Moran L. J. (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol. Metab. 13:251-257.
75. O'Meara N. M., Blackman J.D., Ehrmann D. A., et al. (1993) Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76:1241-1247.
76. Orio Jr. F., Palomba S., Cascella T., et al. (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89:4588-4593.
77. O'Sullivan J. B. (1995) The interaction between pregnancy, diabetes and long-term maternal outcome. In Reece E. A. and Coustan D. R. (eds.) Diabetes Mellitus in Pregnancy, 2nd edn pp.389-398. New York: Churchill Livingstone.
78. Palmert M. R., Gordon C. M., Kartashov A. I., et al. (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87:1017-1023.
79. Paradisi G., Steinberg H.O., Hempfling A., et al. (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410-1415.
80. Pierpoint T., McKeigue P. M., Isaacs A. J., Wild S. H., and Jacobs H. S. (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol. 51:581-586.
81. Pirwany I. R., Fleming R., Greer I. A., Packard C. J., and Sattar N. (2001) Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin. Endocrinol. (Oxf.) 54:447-453.
82. Reaven G. M. (1988) Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-1607.
83. Reaven G. (2002) Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106:286-288.
84. Redberg R. F., Rifai N., Gee L., and Ridker P. M. (2000) Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J. Am. Coll. Cardiol. 36:39-43.
85. Rice S., Christoforidis N., Gadd C., et al. (2005) Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 203:373-381.
86. Ridker P. M., Hennekens C. H., Buring J. E., and Rifai N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:836-843.
87. Robinson S., Chan S. P., Spacey S., et al. (1992) Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin. Endocrinol. (Oxf.) 36:537-543.
88. Robinson S., Kiddy D., Gelding S.V., et al. (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin. Endocrinol. (Oxf.) 39:351-355.
89. Robinson S., Henderson A.D., Gelding S. V., et al. (1996) Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin. Endocrinol. (Oxf.) 44:277-284.
90. Rose G. (1981) Strategy of prevention: lessons from cardiovascular disease. Br. Med. J. (Clin. Res. Edn) 282:1847-1851.
91. Sagle M., Bishop K., Ridley N., et al. (1988) Recurrent early miscarriage and polycystic ovaries. Br. Med. J. 297:1027-1028.
92. Shoupe D., Kumar D.D., and Lobo R. A. (1983) Insulin resistance in polycystic ovary syndrome. Am. J. Obstet. Gynecol. 147:588-592.
93. Solomon C. G., Hu F. B., Dunaif A., et al. (2001) Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. J. Am. Med. Assoc. 286:2421-2426.
94. Speert H. (1949) Carcinoma of the endometrium in young women. Surg. Gynaecol. Obstet. 88:332-336.
95. Stein I. F. and Leventhal M. L. (1935) Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29:181-191.
96. Talbott E.O., Guzick D., Clerici A., et al. (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 15:821-826.
97. Talbott E.O., Clerici A., Berga S. L., et al. (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J. Clin. Epidemiol. 51:415-422.
98. Talbott E.O., Guzick D. S., Sutton-Tyrrell K., et al. (2000) Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20:2414-2421.
99. Taponen S., Martikainen H., Jarvelin M. R., et al. (2003) Hormonal profile of women with selfreported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J. Clin. Endocrinol. Metab. 88:141-147.
100. Taponen S., Martikainen H., Jarvelin M. R., et al. (2004) Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J. Clin. Endocrinol. Metab. 89:2114-2118.
101. Tarkun I., Arslan B. C., Canturk Z., et al. (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J. Clin. Endocrinol. Metab. 89:5592-5596.
102. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19:41-47.
103. Toprak S., Yonem A., Cakir B., et al. (2001) Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm. Res. 55:65-70.
104. Toscano V., Bianchi P., Balducci R., et al. (1992) Lack of linear relationship between hyperinsulinaemia and hyperandrogenism. Clin. Endocrinol. (Oxf.) 36:197-202.
105. Verma S., Buchanan M. R., and Anderson T. J. (2003) Endothelial function testing as a biomarker of vascular disease. Circulation 108:2054-2059.
106. Vrbikova J., Cifkova R., Jirkovska A., et al. (2003) Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum. Reprod. 18:980-984.
107. Wang J. X., Davies M. J., and Norman R. J. (2001) Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum. Reprod. 16:2606-2609.
108. Weerakiet S., Srisombut C., Bunnag P., et al. (2001) Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet. 75:177-184.
109. Weiderpass E., Persson I., Adami H.O., et al. (2000) Body size in diVerent periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 11:185-192.
110. White D. M., Polson D.W., Kiddy D., et al. (1996) Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab. 81:3821-3824.
111. Wild R. A., Painter P. C., Coulson P. B., Carruth K. B., and Ranney G. B. (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 61:946-951.
112. Wild S., Pierpoint T., McKeigue P., and Jacobs H. (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf.) 52:595-600.
113. Willis D. S., Watson H., Mason H.D., et al. (1998) Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 83:3984-3991.
114. Wilson P.W., Abbott R.D., and Castelli W. P. (1988) High density lipoprotein cholesterol and mortality: The Framingham Heart Study. Arteriosclerosis 8:737-741.
115. Yildiz B.O., Yarali H., Oguz H., and Bayraktar M. (2003) Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88:2031-2036.